Guidant gains FDA OK for advanced heart failure system
This article was originally published in Clinica
Executive Summary
The US FDA has cleared for sale Guidant's CONTAK RENEWAL cardiac resynchronisation therapy defibrillator, which it claims is the only such device that can be independently programmed to sense and pace both the left and right ventricles.